Related Experiment Video
Updated: Sep 9, 2026

Production and Testing of Antimicrobial Peptides and Their Mimics
Published on: April 10, 2026
Emerging antimicrobial peptides in gastrointestinal disorders: Dual role in immunity and therapy
Keerthika Selvaraj1, Chandrashekaran Girish2
1Department of Pharmacology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry 605006, Dhanvantari Nagar, India.
Abstract:
Antimicrobial peptides (AMPs) are small, cationic effectors of innate immunity that are central to gastrointestinal homeostasis and increasingly attractive as therapeutics for infection, inflammation, and malignancy. Produced by intestinal epithelial and immune cells, AMPs such as defensins and cathelicidins act as frontline regulators, responding to microbial cues through pattern-recognition receptors, shaping microbiota composition, reinforcing the mucosal barrier, and tuning the balance between pro-inflammatory and anti-inflammatory signalling. This review frames AMP biology around a central duality: The same peptides that defend the gut can, when dysregulated in concentration, location, or context, contribute to pathology, from the α-defensin deficiency that initiates ileal Crohn's disease to the concentration-dependent switch by which LL-37 turns from a wound-healing mediator into a tumour-promoting one. This duality dictates therapeutic strategy, favouring restoration where disease arises from deficiency and restraint where it arises from aberrant signalling. We examine the mechanistic basis of AMP action (membrane disruption, intracellular targeting, and receptor-mediated immunomodulation) and evaluate preclinical and clinical evidence across inflammatory bowel disease, enteric infection, and gastrointestinal cancers, drawing the recurring lesson that microbiological success rarely guarantees clinical benefit. Persistent barriers of proteolytic instability, narrow therapeutic windows, and manufacturing cost are increasingly addressed through convergent advances in artificial intelligence-guided peptide design, sequence stabilisation, gut-targeted and stimulus-responsive delivery, and engineered live biotherapeutics that produce peptides in situ. Together, these developments are transforming AMPs from endogenous immune mediators into next-generation precision therapeutics for gut disease-agents designed to be not merely potent, but deliverable, selective, and stable where needed most.
Related Concept Videos
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Functions of the Gut Microbiota
Microbiota Modulation by Antibiotics
Microorganisms in Medicine and Therapeutics
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

